ArticleInternational ophthalmology2024
The effect of diabetes on short-term outcomes following epiretinal membrane surgery.
Article in International ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vitrectomy for Epiretinal Membrane Peeling in Patients with Diabetic Retinopathy-Functional and Morphological Outcome.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to examine the association of diabetes with anatomical and functional outcomes of epiretinal membrane surgery.
methodsConsecutive patients who underwent epiretinal membrane surgery between 2017-2021 at Helsinki University Hospital, Finland. Here we examined the association of diabetes, glycemic control, and requirement for insulin medication with surgical outcomes at 1-month.
resultsIncluded were 214 eyes of 214 patients, with a mean age of 71.2 ± 8.2 years. Among patients with diabetes (n = 45), neither significant differences were observed in anatomical outcomes (- 47.8 ± 72.7 μm vs. - 38.3 ± 103 μm for foveal thickness, p = 0.566 and - 41.6 ± 61.8 μm vs. - 41.7 ± 85.7 μm for central subfield macular thickness, p = 0.996) nor in best-corrected visual acuity (BCVA) gain (0.06 ± 0.22 vs 0.12 ± 0.30 LogMAR units, p = 0.214) compared to those without diabetes. In a multivariate analysis adjusted for age, gender, the existence of preoperative macular cysts, and topical nonsteroidal anti-inflammatory drugs (NSAIDs) use, the results remained consistent. The last preoperative HbA1c levels did not correlate with changes in foveal (Pearson's r = 0.218, p = 0.264) or central subfield macular thickness (r = 0.365, p = 0.056), or with BCVA gain (r = -0.177, p = 0.386). Insulin therapy for diabetes did not associate with the outcomes (p > 0.05 for anatomical and functional comparisons).
conclusionsIn a cohort of patients who underwent epiretinal membrane surgery, neither the presence of diabetes, nor glycemic control and the use of insulin medication associated with the outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.